Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Bo Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Histone Deacetylase 6, Neuroprotective Agents, Drug Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Shanghai Science and Technology Development Foundation, National Natural Science Foundation of China, National Science and Technology Major Project.
Abstract (Originalsprache)
Histone deacetylase 6 (HDAC6), as the key regulatory enzyme, plays an important role in the development of the nervous system. More and more studies indicate that HDAC6 has become a promising therapeutic target for CNS diseases. Herein we designed and synthesized a series of novel HDAC6 inhibitors with benzothiadiazinyl systems as cap groups and evaluated their activity in vitro and in vivo. Among them, compound 3 exhibited superior selective inhibitory activity against HDAC6 (IC 50 = 5.1 nM, about 30‐fold selectivity over HDAC1). The results of docking showed that compound 3 can interact well with the key amino acid residues of HDAC6. Compound 3 showed lower cytotoxicity (20 μM to SH‐SY5Y cells, inhibition rate = 25.75%) and better neuroprotective activity against L‐glutamate‐induced SH‐SY5Y cell injury model in vitro. Meanwhile, compound 3 exhibited weak cardiotoxicity (10 μM hERG inhibition rate = 17.35%) and possess good druggability properties. Especially, compound 3 could significantly reduce cerebral infarction from 49.87% to 32.18%, and similar with butylphthalide in MCAO model, indicating potential clinical application prospects for alleviating ischemic stroke‐induced brain infarction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, China.
- National Key Laboratory of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry Co. Ltd., Shanghai, China.
- Center for Pharmacological Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China.
- Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Förderung
- Shanghai Science and Technology Development Foundation
- National Natural Science Foundation of China
- National Science and Technology Major Project
Zitieren
APA
Han, B., Gu, X., Wang, M., Wang, H., Sun, N., Yang, X., & Zhang, Q. (2024). Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14556
Vancouver
Han B, Gu X, Wang M, Wang H, Sun N, Yang X, et al. Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14556
BibTeX
@article{Han2024,
author = {Han, Bo and Gu, Xiu and Wang, Mengfei and Wang, Huihao and Sun, Niubing and Yang, Xuezhi and Zhang, Qingwei},
title = {Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14556}
}
EUVIMED